TCMD - Earnings announcements

MINNEAPOLIS, May 04, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Summary and Recent Business Highlights: Total revenue increased 23% year-over-year to $75.3 millionGross margin of 76.5% versus 74% in Q1 2025Net loss of $1.8 million versus $3.0 million in Q1 2025Adjusted EBITDA of $3.7 million versus an Adjusted EBITDA loss of $0.3 million in Q1 2025Expanded AI-enabled order management platform with the implementation of new operational capabilities

MINNEAPOLIS, April 20, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that first quarter of fiscal year 2026 financial results will be released after the market closes on Monday, May 4, 2026. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on May 4, 2026, to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13759535. A live webcast of the call will also be provided on the

MINNEAPOLIS, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Summary: Total revenue increased 21% year-over-year to $103.6 millionGross margin of 78% versus 75% in Q4 2024Net income of $10.6 million versus $9.7 million in Q4 2024Adjusted EBITDA of $22.9 million versus $16.2 million in Q4 2024 Full Year 2025 Summary: Total revenue increased 12% year-over-year to $329.5 millionGross margin of 76%, compared to 74% in 2024Oper

MINNEAPOLIS, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that fourth quarter and fiscal year 2025 financial results will be released after the market closes on Tuesday, February 17, 2026. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on February 17, 2026, to discuss the results of the quarter and fiscal year. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13758303. A live webcast of the call

MINNEAPOLIS, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the third quarter ended September 30, 2025 and announced the adoption of a second share repurchase program. Third Quarter 2025 Summary & Recent Business Highlights: Total revenue increased 17% year-over-year to $85.8 millionGross margin of 76% versus 75% in Q3 2024Net income of $8.2 million versus $5.2 million in Q3 2024Adjusted EBITDA of $14.4 million versus $10.7 million in Q3 2024Announced six-month data demonstrating sustained benefits o

MINNEAPOLIS, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that third quarter of fiscal year 2025 financial results will be released after the market closes on Monday, November 3, 2025. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on November 3, 2025, to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13755883. A live webcast of the call will also be provide

MINNEAPOLIS, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Summary & Recent Business Highlights: Total revenue increased 7.8% year-over-year to $78.9 millionGross margin of 75% versus 74% in Q2 2024Net income of $3.2 million versus $4.3 million in Q2 2024Adjusted EBITDA of $7.7 million versus $9.1 million in Q2 2024Announced the presentation of new data demonstrating significant benefits associated with use of Flexitouch Plus in treatin

MINNEAPOLIS, July 21, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that second quarter of fiscal year 2025 financial results will be released after the market closes on Monday, August 4, 2025. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on August 4, 2025, to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13754589. A live webcast of the call will also be provided o

MINNEAPOLIS, May 05, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Summary & Recent Business Highlights: Total revenue increased 0.3% year-over-year to $61.3 millionGross margin of 74% versus 71% in Q1 2024Net loss of $3.0 million versus $2.2 million in Q1 2024Adjusted EBITDA loss of $0.3 million versus positive Adjusted EBITDA of $1.0 million in Q1 2024Repurchased $10.0 million of stock under the Company's share repurchase programExpanded launch of

MINNEAPOLIS, April 21, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that first quarter of fiscal year 2025 financial results will be released after the market closes on Monday, May 5, 2025. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on May 5, 2025, to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13752588. A live webcast of the call will also be provided on the

MINNEAPOLIS, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Summary & Recent Business Highlights: Total revenue increased 10% year-over-year to $85.6 millionGross margin of 75% versus 72% in Q4 2023Net income of $9.7 million versus $8.2 million in Q4 2023Adjusted EBITDA of $16.2 million versus $15.4 million in Q4 2023Expanded launch of Nimbl to include patients with lower extremity lymphedemaAppointed Laura King to Board of

MINNEAPOLIS, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that fourth quarter and fiscal year 2024 financial results will be released after the market closes on Tuesday, February 18, 2025. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on February 18, 2025, to discuss the results of the quarter and fiscal year. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13751026. A live webcast of the call

MINNEAPOLIS, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the third quarter ended September 30, 2024 and announced the adoption of a share repurchase program. Third Quarter 2024 Summary & Recent Business Highlights: Total revenue increased 5% year-over-year to $73.1 million Lymphedema product revenue increased 4% over Q3 2023Airway clearance product revenue increased 10% over Q3 2023 Net income of $5.2 million versus $22.3 million in Q3 2023Adjusted EBITDA of $10.7 million versus $7.7 million in Q3

MINNEAPOLIS, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that third quarter of fiscal year 2024 financial results will be released after the market closes on Monday, November 4, 2024. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on November 4, 2024, to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13748661. A live webcast of the call will also be provide

MINNEAPOLIS, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Highlights: Total revenue increased 7% year-over-year to $73.2 million Lymphedema product revenue increased 8% year-over-yearAirway clearance product revenue increased 2% year-over-year Net income of $4.3 million versus a net loss of $0.1 million in Q2 2023Adjusted EBITDA of $9.1 million versus $6.1 million in Q2 2023Operating cashflow of $13.1 million, ended Q2 2024 with $73.6 mill

MINNEAPOLIS, July 22, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that second quarter of fiscal year 2024 financial results will be released after the market closes on Monday, August 5, 2024. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on August 5, 2024, to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13745955. A live webcast of the call will also be provided o

MINNEAPOLIS, May 06, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Summary: Total revenue increased 4% year-over-year to $61.1 million Lymphedema product revenue increased 5% year-over-yearAirway clearance product revenue decreased 4% year-over-year Net loss of $2.2 million versus $1.9 million in Q1 2023Adjusted EBITDA of $1.0 million versus $0.5 million in Q1 2023 Recent Business Highlights: Completed enrollment of 235 patients in a multi-center,

CEO Dan Reuvers to retire; Healthcare veteran and board director Sheri Dodd appointed as Chief Executive OfficerPreliminary, unaudited total revenue for first quarter of 2024 expected to be approximately $61 millionManagement to host conference call on May 6, 2024 to discuss first quarter 2024 financial results MINNEAPOLIS, April 23, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that Dan Reuvers will retire as the Company's Chief Executive Officer, effective June 30, 2024. Concurrently, the Company announced the appointment of

MINNEAPOLIS, April 15, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that first quarter of fiscal year 2024 financial results will be released after the market closes on Monday, May 6, 2024. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on May 6, 2024, to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13745955. A live webcast of the call will also be provided on the

MINNEAPOLIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 Highlights: Total revenue increased 5% over prior year to $77.7 millionNet income increased 77% over prior year to $8.2 millionAdjusted EBITDA increased 27% over prior year to $15.4 millionRetired $16.8 million revolving line of credit and completed final $5.6 million ea

MINNEAPOLIS, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that fourth quarter and fiscal year 2023 financial results will be released before the market opens on Tuesday, February 20th. Management will host a conference call with a question and answer session at 8:00 a.m. Eastern Time on February 20th to discuss the results of the quarter and fiscal year. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13744163. A live webcast of the call will als

MINNEAPOLIS, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the third quarter ended September 30, 2023. Third Quarter 2023 Summary: Revenue increased 7% year-over-year to $69.6 million, compared to $65.3 million in third quarter 2022 Lymphedema revenue increased 15%Airway clearance revenue decreased 36% Operating income of $8.0 million, compared to operating loss of $1.6 million in third quarter 2022Net income of $22.3 million, compared to a net loss of $2.3 million in third quarter 2022Adjusted EBIT

MINNEAPOLIS, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that third quarter of fiscal year 2023 financial results will be released after the market closes on Monday, November 6. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on November 6 to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13741621. A live webcast of the call will also be provided on the inve

MINNEAPOLIS, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the second quarter ended June 30, 2023. Second Quarter 2023 Highlights: Revenue increased 15% year-over-year to $68.3M Lymphedema revenue increased 16%Airway Clearance revenue increased 4% Operating income of $2.1M, compared to operating loss of $4.1MNet loss of $0.1M, compared to a net loss of $4.6MAdjusted EBITDA of $6.1M, up from $1.7MCash Balance of $63.1M on June 30, 2023, compared to $55M on March 31, 2023Raised full year 2023 fi

MINNEAPOLIS, June 29, 2023 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that second quarter of fiscal year 2023 financial results will be released after the market closes on Monday, August 7. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on August 7 to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13739727. A live webcast of the call will also be provided on the investo

MINNEAPOLIS, March 30, 2023 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that first quarter of fiscal year 2023 financial results will be released after the market opens on Monday, May 8. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on May 8 to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13737578. A live webcast of the call will also be provided on the investor relat

MINNEAPOLIS, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the fourth quarter and full year ended December 31, 2022. Fourth Quarter 2022 Summary: Total revenue increased 20% year-over-year to $73.9 million, compared to $61.7 million in fourth quarter 2021 Revenue from lymphedema products increased 14% year-over-year to $65.8 millionRevenue from airway clearance products increased 90% year-over-year to $8.1 million Operating income of $7.9 million, compared to $3.8 million in fourth quarter 2021 Non-GAAP operating

MINNEAPOLIS, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that fourth quarter and fiscal year 2022 financial results will be released before the market opens on Tuesday, February 21st. Management will host a conference call with a question and answer session at 8:00 a.m. Eastern Time on February 21st to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13736241. A live webcast of the call will also be provided on the investor r

MINNEAPOLIS, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical") (NASDAQ:TCMD), a medical technology company focused on developing medical devices for the treatment of patients with underserved chronic diseases at home, today reported financial results for the third quarter and nine months ended September 30, 2022. Third Quarter 2022 Summary: Total revenue increased 24% year-over-year to $65.3 million, compared to $52.5 million in third quarter 2021. Total revenue in third quarter 2022 included $11.0 million of revenue from sales of airway clearance products, which includes the AffloVest product line acquired on September 8, 2021, c

MINNEAPOLIS, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical") (NASDAQ:TCMD), a medical technology company focused on developing medical devices for the treatment of patients with underserved chronic diseases at home, today announced that third quarter of fiscal year 2022 financial results will be released after the market closes on Monday, November 7th. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on November 7th to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13733034. A live webcast

MINNEAPOLIS, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical") (NASDAQ:TCMD), a medical technology company focused on developing medical devices for the treatment of patients with underserved chronic diseases at home, today reported financial results for the second quarter and six months ended June 30, 2022. Second Quarter 2022 Summary: Total revenue increased 17% year-over-year to $59.6 million, compared to $51.1 million in second quarter 2021. Total revenue in second quarter 2022 included $8.0 million of revenue from sales of airway clearance products, which includes the AffloVest product line acquired on September 8, 2021. Operating loss of $

MINNEAPOLIS, July 12, 2022 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical") (NASDAQ:TCMD), a medical technology company focused on developing medical devices for the treatment of patients with underserved chronic diseases at home, today announced that second quarter of fiscal year 2022 financial results will be released after the market closes on Monday, August 1st. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on August 1st to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13731068. A live webcast of

MINNEAPOLIS, May 02, 2022 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical") (NASDAQ:TCMD), a medical technology company focused on developing medical devices for the treatment of patients with underserved chronic diseases at home, today reported financial results for the first quarter ended March 31, 2022. First Quarter 2022 Summary: Total revenue increased 12% year-over-year to $48.0 million, compared to $42.8 million in first quarter 2021. Total revenue in first quarter 2022 included $7.3 million of revenue from sales of airway clearance products, which includes the AffloVest product line acquired on September 8, 2021. Operating loss of $14.9 million, compared to

MINNEAPOLIS, March 31, 2022 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical") (NASDAQ:TCMD), a medical technology company focused on developing medical devices for the treatment of patients with underserved chronic diseases at home, today announced that first quarter of fiscal year 2022 financial results will be released after the market closes on Monday, May 2nd. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on May 2nd to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13728512. A live webcast of the ca

MINNEAPOLIS, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical") (NASDAQ:TCMD), a medical technology company focused on developing medical devices for the treatment of patients with underserved chronic diseases at home, today reported financial results for the fourth quarter and full year ended December 31, 2021. Fourth Quarter 2021 Summary: Total revenue increased 4% year-over-year to $61.7 million, compared to $59.2 million in fourth quarter 2020. Total revenue in fourth quarter 2021 included $4.3 million of revenue from the AffloVest respiratory therapy business, acquired on September 8, 2021. Operating income of $3.8 million, compared to operating i

MINNEAPOLIS, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical") (NASDAQ:TCMD), a medical technology company focused on developing medical devices for the treatment of patients with underserved chronic diseases at home, today announced that fourth quarter and fiscal year 2021 financial results will be released after the market closes on Tuesday, February 22nd. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on February 22nd to discuss the results of the quarter and the fiscal year. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code

MINNEAPOLIS, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical") (NASDAQ:TCMD), a medical technology company focused on developing medical devices for the treatment of underserved chronic diseases at home, today reported financial results for the third quarter and nine months ended September 30, 2021. Third Quarter 2021 Summary: Total revenue increased 7% year-over-year to $52.5 million, compared to $49.1 million in third quarter 2020. Total revenue in third quarter 2021 included $0.9 million of revenue from the recently acquired AffloVest respiratory therapy business. Operating loss of $1.4 million, compared to operating income of $1.8 million in third

MINNEAPOLIS, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical") (NASDAQ:TCMD), a medical technology company focused on developing medical devices for the treatment of underserved chronic diseases at home, today announced that third quarter of fiscal year 2021 financial results will be released after the market closes on Monday, November 8th. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on November 8th to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13723889. A live webcast of the call wi

MINNEAPOLIS, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical") (NASDAQ:TCMD), a medical technology company focused on developing medical devices for the at-home treatment of chronic diseases, today reported financial results for the second quarter and six months ended June 30, 2021. Second Quarter 2021 Summary: Total revenue increased 45% year-over-year to $51.1 million, compared to $35.1 million in second quarter 2020.Operating loss of $0.1 million, compared to operating loss of $8.0 million in second quarter 2020.Net income of $1.3 million, compared to net loss of $13.9 million in second quarter 2020.Adjusted EBITDA of $4